We are pleased to share that o2h Discovery has once again been named a finalist, this year for the category “Pharma Contract Services Company of the Year” at the Pharmaceutical Industry Awards (PIA) UK 2025. The PIA UK Awards celebrate excellence and innovation across the pharmaceutical sector, recognising organisations that are making a measurable difference to drug discovery, development, and delivery. Check the shortlists and read more about the award here.

The Pharma Contract Services Company of the Year category highlights companies that have demonstrated strong performance in providing contract research and development services, delivering high-quality science, supporting innovation pipelines, and fostering long-term partnerships with biotech and pharma clients. Being shortlisted in this category reflects our continued investment in scientific expertise, advanced infrastructure, and collaborative approaches that enable our partners to advance their programmes more effectively.

This recognition follows on from last year, when our proprietary app CITC (Chemistry in the Cloud™) won the “Best Use of Technology Award” at the Pharma Industry Awards UK 2023. Together, these acknowledgements reinforce our commitment to scientific innovation, digital transformation, and high-quality service delivery across the entire drug discovery value chain. Read the full blog here.

Our scientific teams in Cambridge, UK and Ahmedabad, India continue to work closely with partners on integrated discovery projects spanning medicinal chemistry, biology, DMPK, and scale-up. At o2h Discovery, we remain dedicated to supporting the global life sciences ecosystem and contributing to breakthroughs that bring new medicines closer to patients.

About o2h Discovery

Founded in 2005, o2h Discovery is a multi-award-winning CRO with a multi-modality integrated drug discovery platform, operating from Cambridge, UK, and Ahmedabad, India. We execute hit-to-lead optimisation programmes leading into patent and IND filing, with deep expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development.

We have experienced scientists who deliver a comprehensive range of custom peptide synthesis services, from small quantities of a few milligrams to larger amounts at the gram scale. Our capabilities go beyond standard fast custom peptide synthesis services (o2h Peptide Guarantee), offering specialised peptide modification services to customise and optimise peptides for diverse drug discovery programs. Our clients include large pharma companies, leading academic institutions, and biotech firms. 

o2h Discovery’s large team of experts also delivers high-quality services, covering DMPK, scale-up/PR&D, PROTAC’s (Protac Synthesis Services), LNPs, various assays, including ChamelogK, supporting organisations of all sizes with cost-effective solutions from target validation all the way to IND-enabling studies.

The DNA of o2h discovery is centred around the nurturing of its people, values, and culture. It reflects in the way we work with each other, as well as our collaborators and partners. 

Latest Update: Building on the encouraging response from our previous Kickstarter editions, we are pleased to share the launch of the o2h Kickstarter Japan campaign. With this initiative, we aim to share our expertise in close collaboration with Japan’s vibrant and fast-growing biotech ecosystem. For more information, please visit the official website – o2h Kickstarter: Japan